Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax Inc (NASDAQ: NVAX) has told the European Union it plans to begin delivering its COVID-19 vaccine to the bloc towards the end of this year, A formal contract could be signed as early as this week, an E.U. official told Reuters.

Europe To Get Novavax COVID-19 Vaccines But Not Before End Of 2021: Reuters

Novavax Inc (NASDAQ: NVAX) has initiated a pediatric expansion of its Phase 3 PREVENT-19 trial for NVX-CoV2373, its COVID-19 vaccine candidate. The additional arm of the ongoing PREVENT-19 pivotal trial will evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 in up to 3,000 adolescents aged 12-17.

Novavax Next In List To Start Testing Its COVID-19 Shot In Adolescents

Shares of Novavax Inc. gained 0.6% in trading on Monday after the biotechnology firm said it has expanded its Phase 3 clinical trial for its COVID-19 vaccine candidate to include 12 to 17 year olds in the U.S. Novavax's experimental vaccine is currently being tested in a late-stage trial that began in December in the U.S. and Mexico. The pediatric arm aims to enroll 3,000 teens.

Novavax begins testing its COVID-19 vaccine candidate in teens

GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19.

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.

Novavax (NVAX) Stock Moves -0.25%: What You Should Know

According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to develop a COVID-19 vaccine dubbed NVX-CoV2373. This addition brings its total from the program to $1.74 billion, which was announced in July last year.

Novavax Secures Additional $147M From Warp Speed Program For COVID-19 Vaccine

Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.

Novavax Vaccine to Get U.S. Approval? ETFs to Benefit

NVAX stock has gained almost 50% over the last month and trades at levels of around $258. So what's driving the surge in the stock?

What Is Driving Novavax Stock?

On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

NVAX stock looks to gain for a third straight day as Biden eyes using the Novavax Covid-19 shot to help with international aid. The post NVAX Stock: The Big Covid-19 Vaccine News Lifting Novavax Today appeared first on InvestorPlace.

NVAX Stock: The Big Covid-19 Vaccine News Lifting Novavax Today

Shares of Novavax Inc surged 16% in extended trading on Tuesday after President Joe Biden said the United States was planning to share COVID-19 vaccines with countries in need of aid.

Novavax shares jump after Biden says focusing on its vaccine

The company's coronavirus vaccine was mentioned by a very powerful person.

Why Novavax Stock Popped Today

Shares of Novavax Inc. gained 12.1% in trading on Tuesday after President Joe Biden mentioned that the company's experimental COVID-19 vaccine may be nearing emergency-use authorization in the U.S. "The problem is right now we have to make sure we have other vaccines like Novavax and others coming on," he said during a speech. "And I think we'll be in a position to be able to share vaccines with other countries who are in real need.

Novavax's stock jumps after Biden mentions its COVID-19 vaccine candidate

The Matrix-M adjuvant is increasingly looking like Novavax's crown jewel.

This Huge Win Could Boost Novavax's Fortunes -- and It Has Nothing to Do With COVID-19

Sure there's competition among vaccine makers, but there's no reason to sell your NVAX stock as the company releases encouraging data. The post Stand By Novavax as Pivotal Trials Push Boundaries of Vaccine Science appeared first on InvestorPlace.

Stand By Novavax as Pivotal Trials Push Boundaries of Vaccine Science

GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2021 financial results and operational highlights on Monday, May 10, 2021, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021

Inovio Pharmaceuticals

Protara Therapeutics Inc

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Data: Novavax, which is in the final legs of completing the COVID-19 vaccine race, is moving on success in another arena.

Why Novavax, Inovio, and Protara Are Moving Today

Novavax Inc (NASDAQ: NVAX) has announced the pre-print publication of data from a Phase 2b trial in children evaluating its malaria vaccine candidate, R21, created by the University of Oxford. The three arms study recruited 450 participants.

Novavax's Malaria Vaccine Candidate Shows 77% Efficacy In Mid-Stage Study

GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax' Matrix-M™ adjuvant and is licensed to Serum Institute of India (SII).

Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet

The biotech could benefit from more supply deals.

Why Novavax Could Be the Biggest Winner From Johnson & Johnson's Vaccine Woes

Moderna

The Moderna CEO's Bold Statement That May Mean Bad News for Novavax

The European Union could bolster the biotech's coronavirus revenue.

Novavax Is Missing Out on a Big Deal

Editas Medicine

FibroGen

All down 45% or more from their 52-week highs, should you consider cutting your losses?

3 Biotech Stocks Ripe for Spring Portfolio Cleaning

The extended pause for Johnson & Johnson's coronavirus vaccine in the U.S. could bolster vaccine stocks Pfizer, Moderna and Novavax, experts say. And the question of herd immunity looms.

How J&J's Coronavirus Vaccine Fiasco Could Benefit Novavax And Others

Johnson & Johnson

Novavax (NASDAQ: NVAX) stock rallied by over 10% after the U.S. Food and Drug Administration and the U.S. Centers for Disease Control paused the rollout of Johnson & Johnson's Covid-19 vaccine in the U.S. following some rare, yet severe incidents of blood clotting.

News for Novavax Stock (NVAX)